Drug Profile
Research programme: inflammatory bowel disease therapeutics - Janssen/Mount Sinai
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Icahn School of Medicine at Mount Sinai; Janssen Biotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammatory-bowel-disease in USA
- 27 Jun 2013 Janssen Biotech establishes CRADA with The Icahn School of Medicine at Mount Sinai for the development of a research programme in Inflammatory bowel disease
- 27 Jun 2013 Early research in Inflammatory bowel disease in USA